

3rd Annual Academic & Industry Intersection Conference

COMMERCIALIZATION OF DISCOVERIES

February 9, 2012 | 11:30am-5:30pm



AGENDA

11:30 a.m.-12:30 p.m. Registration Opens / Networking

Lunch, Emory Conference Center Dining Room

12:30-12:40 p.m. Introductory Remarks

David S. Stephens, MD Principal Investigator, Atlanta Clinical & Translational Science Institute; Vice President for Research, Robert W. Woodruff Health Sciences Center, Emory University

Charles Craig, President, Georgia Bio

Leslie Saunders, AIA, ACHA, LEED AP, Senior Strategic Facilities Planner, Flad Architects

12:40-1:40 p.m. Keynote Speakers:

Academic Drug Development & Industry's Device Development

George Painter, PhD, Principal Scientist, Emory College, Emory Institute for Drug Discovery

Douglas B. Schumer, PhD, General Manager, Global Center for Medical Innovation

1:40-2:10 p.m. Break

2:10-3:40 p.m. Georgia Success Stories

Moderator: **Todd Sherer**, PhD, Director Technology Transfer, Emory University

Christian Larsen, MD, DPhil, Joseph Brown Whitehead Professor and Chairman, Department of Surgery, Emory University School of Medicine

Mary Beth Harler, Executive Director, Global Development, Bristol-Myers Squibb

Joseph M. Patti, M.S.P.H., Ph.D., Co-Founder, Chief Scientific Officer & Senior Vice President of Research and Development, Inhibitex, Inc.

Daniel White, MBA, President and Chief Executive Officer, Clearside Biomedical, Inc.

Mark R. Prausnitz, PhD, Regents' Professor and Love Family Professor in Chemical & Biomolecular Engineering, School of Chemical Engineering, Georgia Institute of Technology

3:40-4:10 p.m. Break

4:10-5:30 p.m. GRA Venture Lab Fellow Vignettes & Announcement of State-wide Pilot Award

Moderator: **Lee Herron**, DVM, Vice President of Commercialization, Georgia Research Alliance

AKESOgen - Emory University

Amniox Medical - Georgia Institute of Technology

Cambium Medical Technologies - Emory University

General Genomics - Georgia Institute of Technology

InViza Technologies - Emory University

OncoVaxine - Emory University

Viamune - University of Georgia

XPClad - Morehouse School of Medicine

Presented By



Atlanta Clinical
& Translational
Science Institute

GEORGIA BIO[™]
The Life Sciences Partnership

3rd Annual Academic & Industry Intersection Conference

COMMERCIALIZATION OF DISCOVERIES



February 9, 2012 | 11:30am-5:30pm

Emory Conference Center Amphitheater | 1615 Clifton Road, Atlanta, GA 30329

BIOGRAPHIES

George Painter, PhD

Principal Scientist, Emory College, Emory Institute for Drug Discovery

George Painter has 24 years of experience in the discovery and development of pharmaceutical agents, and most recently held the position of Executive Vice President, Research and Development at Triangle Pharmaceuticals where he was a member of the founding management team. In addition to his management experience at Triangle Pharmaceuticals, Dr. Painter held positions at Burroughs Wellcome Co. beginning in 1983 including Director of Chemistry and Director of Virology. Subsequently, he served as Director of Research Process and International Deputy Therapeutic Head for Antiviral Research at Glaxo Wellcome Inc. Dr. Painter is a co-inventor of over 45 patents, six of which have led to approved commercially available drugs or combinations of drugs for the treatment of HIV and hepatitis B. He has led international teams, which generated data for nine investigational new drug applications and three new drug applications. Dr. Painter earned a BS in chemistry, an MS in physical organic chemistry and a PhD in synthetic chemistry from Emory University.

Douglas B. Schumer, Ph.D.

General Manager, Global Center for Medical Innovation

Dr. Schumer is General Manager for GCMI, the Global Center for Medical Innovation, with headquarters in Atlanta, coming most recently from Georgia Tech as its first George W. Woodruff School Director of Design Innovation and Instruction. His education was in physics and electrical and systems engineering, with bachelors and masters degrees from Carnegie-Mellon University (Pittsburgh, PA) and his doctorate from Rensselaer Polytechnic Institute of Technology (Troy, NY).

Dr. Schumer has over 30 years of industry experience, of which the last 20 were with medical device companies as general manager or as the senior executive leading Research and Development. Among those companies are Guidant CRM, Novoste, Thoratec, Animas/J&J, TDC Medical and CardioMEMS. Breakthrough technology and products for which he led development include first-to-market concepts in pacemakers, implantable defibrillators, heart assist devices, devices for the treatment of coronary artery disease, wearable insulin pumps and miniature implantable sensors for home-monitoring of congestive heart failure patients. These product platforms now account for over 200 PMA and PMA-supplement products approved by the FDA.

Dr. Schumer has led several industry-university research collaborations. He established the world-class Cardiac Rhythm Management Research Lab at the University of Alabama, Birmingham, which developed fundamental technology and IP in AF ablation, biventricular pacing for congestive heart failure and fundamental defibrillation technology.



Atlanta Clinical
& Translational
Science Institute

Presented By

GEORGIA BIO™
The Life Sciences Partnership

BIOGRAPHIES

Todd Sherer, PhD, Executive Director, Technology Transfer; Associate VP for Research Administration, Emory University

Dr. Sherer leads a team of 20 focused on creating value from intellectual property developed by Emory researchers. Since joining Emory in 2003, Dr. Sherer has expanded the program by 12 staff, instituted a commercially oriented product pipeline to highlight Emory's varied portfolio and created an in-house patent department to reduce costs and better align patent work with research activity. His new initiatives have transformed the office's focus from one of transactional support to one of value creation. Licensing revenues have exceeded \$650M since he joined the office. Dr. Sherer also worked with colleagues to monetize downstream licensing revenues on an Emory-discovered molecule that is now part of the leading AIDS drug cocktail - resulting in a \$540M, one-time payment from the licensee, Gilead Sciences. Over 90% of HIV patients in the U.S. and Europe on life saving anti-viral therapy take a drug developed at Emory University.

Before joining Emory, Dr. Sherer was Director of Technology and Research Collaborations at Oregon Health & Science University in Portland where he worked with senior officials to secure \$200M from the State for the Oregon Opportunity. At the University of Oregon in Eugene, he was Director of the Office of Technology Transfer, and worked with a diverse portfolio of intellectual property in the computer sciences, telecom and the biological sciences. He began his career in technology development at Washington State University, achieving the level of Associate Director of the Office of Intellectual Property Administration. A scientist and administrator, he earned his BS at Oregon State University and his PhD at Washington State University. He began his science career in developmental toxicology at Battelle's Pacific Northwest National Laboratories.

Dr. Sherer is the in-coming President-Elect for the Association of University Technology Managers (AUTM) where he has held several other board positions in the past. He is also on the Board of Directors of Southeast BIO (SEBIO). He sits on the selection panel for several translational research funds including the VentureLab program for the Georgia Research Alliance and the Coulter Translational Research Fund. He also consults frequently for the AAAS and state organizations. Dr. Sherer is a Registered Patent Agent with the U.S. Patent and Trademark Office and a Certified Licensing Professional.

Christian P. Larsen, MD, DPhil Joseph Brown Whitehead Professor and Chairman, Department of Surgery, Emory University School of Medicine Associate Vice President and Executive Director, Emory Transplant Center, Emory Surgeon-in-Chief, Emory University Hospital, Director of Surgical Services, Emory Healthcare, Co-Director, Kidney/Pancreas Transplant Program, Emory University Hospital

Christian P. Larsen, MD, DPhil, has made seminal contributions to the investigation of the immunologic mechanisms of transplant rejection and immunologic tolerance and is an internationally recognized leader in kidney, pancreas and islet transplantation. Dr. Larsen received his medical degree magna cum laude from Emory in 1984 and his Doctor of Philosophy in transplantation immunology from the University of Oxford, England, in 1990. After completing his general and transplantation surgery training at Stanford and Emory, where he was chief resident in surgery and a fellow in transplantation surgery, he was appointed to the faculty of the Emory University Department of Surgery in 1991.

Dr. Larsen is a leading transplant surgeon and immunologist, a frequent author of high-impact journal publications, and a translator of discoveries from the bench to the bedside. He was the first researcher to demonstrate the migration of dendritic cells from a transplanted organ to the draining lymph node or spleen, where the cells initiate the immune response that can cause allograft rejection. With others, he initiated the Emory Transplantation Immunology Lab, which has played a pivotal role in developing a new class of immunosuppressive drugs, the costimulation blockers and a new transplant immunosuppressant named belatacept. Dr. Larsen's current scientific endeavors are also focused on achieving immunological tolerance through the induction of mixed hematopoietic chimerism and on the application of costimulation blockers to facilitate transplantation of insulin-producing cells (islets) to treat type 1 diabetes. Dr. Larsen performed the first islet transplant in Georgia in 2003.

He has been continuously funded by the NIH, is the recipient of a NIH MERIT award and has directed program project grants, center awards and multi-institutional consortia from the NIH and Juvenile Diabetes Research Foundation. Dr. Larsen is an elected member of the American Society for Clinical Investigation and is the recipient of many national and international research awards.

BIOGRAPHIES

Mary Beth Harler, MD

Executive Director, Global Development, Bristol-Myers Squibb

Mary Beth Harler is the Development Lead for belatacept, a novel biologic developed for use in kidney transplantation. Prior to joining Bristol-Myers Squibb, Dr. Harler was an Assistant Vice President in Clinical Research and Development at Pfizer/Wyeth. She completed her surgical training at Brown University School of Medicine where she was also an immunology research fellow and a Clinical Instructor in the Department of Surgery.

Joseph M. Patti, M.S.P.H., Ph.D.

Co-Founder, Chief Scientific Officer and Senior Vice President of Research and Development

Joseph M. Patti, M.S.P.H., Ph.D. is a co-founder of Inhibitex, Inc. and has served as the Chief Scientific Officer and Senior Vice President of Research and Development since 2007. He served as the Vice President, Preclinical Development and Chief Scientific Officer of the Company from 1998 to 2007 and Vice President of Research and Development from 2005 to 2007. From 1994 to 1998, Dr. Patti was an assistant professor at Texas A&M's Institute of Biosciences and Technology. From 1996 to 1998, he served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. He currently holds an adjunct faculty position in the biology department at Georgia State University. Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, an M.S.P.H. from the University of Miami, School of Medicine and a Ph.D. in Biochemistry from the University of Alabama at Birmingham.

Daniel White, MBA

President and Chief Executive Officer, Clearside BioMedical Inc, Georgia

Daniel White is President and CEO of Clearside BioMedical, Inc, a development stage company focused on a device that provides access to tissue specific delivery of drugs initially designed for ophthalmic applications that may be incorporated into the common medical practice for the treatment of retinal disease, glaucoma, and dry eye. Prior to joining Clearside BioMedical, Mr. White served in Global Corporate Development as head of transactions for GSK's dermatology division of Stiefel. He has participated in private equity raises and sales of assets for over \$120 million and has played an integral role in the negotiation of 27 acquisitions and divestitures. Product successes include seven launched products and two late phase III products associated with assets identified, licensed or acquired. He was a founding member and instrumental in the creation of two start-up companies: Percept BioSciences, Inc., an Atlanta based R&D start-up in Attention Deficit and Hyperactivity Disorder and Alimera Sciences, Inc (ALIM) now a publically traded, Atlanta-based specialty pharmaceutical company developing drugs for prescription and OTC ophthalmology indications where he served as Vice President of Finance and Corporate Development. He has previously held management positions in global corporate development with Novartis subsidiary, CIBA Vision and aaiPharma, and has developed numerous health sciences industry contacts, VCs and investment banks. He has proven success in-licensing and business development, acquisition and divestiture, development/supply agreements, intellectual property and contracts, corporate finance and fundraising and international development. Mr. White holds an MBA from Wake Forest in Finance, and has undergraduate degree in Molecular Biology from Auburn University and graduate work in pharmacology from the University of North Carolina at Chapel Hill.

Mark R. Prausnitz, PhD

Regents' Professor and Love Family Professor in Chemical & Biomolecular Engineering, School of Chemical Engineering, Georgia Institute of Technology

Mark Prausnitz carries out research on biophysical methods of drug delivery, which employ microneedles, ultrasound, lasers, electric fields, heat, convective forces and other physical means to control the transport of drugs, proteins, genes and vaccines into and within the body. A major area of focus involves the use of microneedle patches to apply vaccines to the skin in a painless, minimally invasive manner. In collaboration with Emory University, the Centers for Disease Control and Prevention and other organizations, Dr. Prausnitz and his colleagues are advancing microneedles from device design and fabrication through pharmaceutical formulation and pre-clinical animal studies through studies in human subjects. In addition to developing a self-administered influenza vaccine using microneedles, he is translating microneedles technology especially to make vaccination in developing countries more effective. In addition to research activities, he teaches and also serves the broader scientific and business communities as a frequent consultant, advisory board member and expert witness. Dr. Prausnitz received a BS with distinction in Chemical Engineering from Stanford University and a PhD in Chemical Engineering from Massachusetts Institute of Technology.

BIOGRAPHIES

H. Lee Herron, DVM, Vice President of Commercialization, Georgia Research Alliance

Just prior to joining the Georgia Research Alliance (GRA), Dr. Herron was General Manager, Biosciences, for the Advanced Technology Development Center (ATDC). In this capacity, Dr. Herron advised start-up and early stage companies regarding the growth and development of their organizations. Through the GRA VentureLab program at Georgia Tech, he worked with faculty at Georgia Tech to evaluate commercial opportunities and to pursue new venture formation or licensing opportunities. He also served as CEO EmTech Bio, a collaborative program of Georgia Tech and Emory.

Before joining ATDC, Dr. Herron worked with BRAHMS AG, a German manufacturer of in-vitro diagnostic products, to establish its North American operations. Earlier, he was the founder, President and CEO of SeaLite Sciences, Inc., a company focused on the development and commercialization of diagnostic products and molecular biology reagents. Dr. Herron was also a founding team member of three other bioscience companies, Biopool International, Inc., CytRx Corporation and Theragenics Corporation. He earned his Doctor of Veterinary Medicine degree from the University of Georgia.

Company	University	Description
AKESOgen	Emory University	AKESOgen is providing a genomics CRO service to the academic, pharmaceutical, biotechnology and agricultural sectors.
Amniox Medical	Georgia Institute of Technology	Amniox is pursuing the development and commercialization of processed amniotic membrane tissue for use as a scaffold for tissue engineering applications targeting cartilage and bone repair.
Cambium Medical Technologies	Emory University	Cambium is developing a topical solution derived from platelets for ophthalmologic indications associated with corneal disease
General Genomics	Georgia Institute of Technology	General Genomics is developing a novel platform that exploits evolutionary analyses to guide the engineering of proteins. The initial product of this application is intended to treat human gout.
InViza Technologies	Emory University	InViza is a project focused on the development of a suite of software tools for web-based early detection of memory impairment associated with Alzheimer's disease before the disease is detectable by other means.
OncoVaxine	Emory University	The goal of this project is to prepare highly immunogenic cancer vaccines to treat patients against metastasizing cancers. The vaccines will be produced by introducing various immunostimulatory molecules into tumor membranes derived from patient's tumor tissue.
Viamune	University of Georgia	Viamune is developing an anti-cancer immunotherapy based on a glycopeptide vaccine. The vaccine is currently in pre-clinical testing at the Mayo Clinic.
XPClad	Morehouse School of Medicine	This project is focused on developing a novel nanoparticle platform for the targeted delivery of taxanes and platinum-based drugs for cancer therapy.